Advertisement

Topics

Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma

2016-08-11 08:23:21 | BioPortfolio

Summary

This study aims to realize an economic evaluation of the introduction of Plerixafor in addition to G-CSF and alternative options, in patients with multiple myeloma (MM) who failed or insufficiently mobilize peripheral blood stem and progenitor cells in response to G-CSF alone.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Conditions

Multiple Myeloma

Intervention

Economic evaluation

Location

Institut Paoli-Calmettes
Marseille
Bouches-du Rhône
France
13009

Status

Completed

Source

Institut Paoli-Calmettes

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-08-11T08:23:21-0400

Clinical Trials [1571 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment....

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and fe...

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma. Cardiac amyloido...

Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory mul...

PubMed Articles [13198 Associated PubMed Articles listed on BioPortfolio]

Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT.

A 60-year-old woman diagnosed with multiple myeloma was referred for Ga-pentixafor PET/CT for evaluation of the disease. Diffuse and intense radioactivity throughout the axial and proximal appendicula...

Organochlorine Levels in Plasma and Risk of Multiple Myeloma: Organochlorines and risk of multiple myeloma.

To estimate the association between organochlorine pesticides and polychlorinated biphenyls (PCBs) and multiple myeloma (MM).

Severe Cytomegalovirus Enterocolitis Developing following Daratumumab Exposure in Three Patients with Multiple Myeloma.

Survival of multiple myeloma (MM) patients has improved with introduction of novel anti-myeloma agents. Myeloma has transformed into a chronic condition, accompanied with multiple relapses requiring s...

Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis.

Multiple myeloma (MM) is a common malignancy belonging to the hematological system. The translocation t(4;14)(p16.3;q32.3) is a critical cytogenetic change of MM, which is presenting a poor prognosis....

Multiple Myeloma - Current Standards in Surgical Treatment.

Multiple myeloma is a haematological blood cancer in elderly patients, in which neoplastic cell populations cause osteolytic destruction in the bone skeleton. More than 50% of all patients sustain pat...

Medical and Biotech [MESH] Definitions

An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

An international organization whose mission is to stimulate world trade and economic progress by offering a forum where governments can collectively develop and refine social and economic policies.

An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.

More From BioPortfolio on "Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial